We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Novo Nordisk and Eli Lilly's motion to dismiss took aim at most of the counts asserted in the plaintiffs’ master long-form ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly ( LLY 2.45%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival. That ...

U.S. drugmaker Pfizer PFE.N is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The Wabash Valley Community Foundation has landed a $6.5 million grant toward an $11.3 million modernization and renovation ...

Neurocrine Biosciences, Inc. today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the ...